Equities Analysts Offer Predictions for Inhibrx, Inc.’s Q1 2023 Earnings (NASDAQ:INBX)

Inhibrx, Inc. (NASDAQ:INBX – Get Rating) – Stock analysts at Jefferies Financial Group issued their Q1 2023 EPS estimates for Inhibrx in a research note issued on Monday, May 9th. Jefferies Financial Group analyst M. Yee forecasts that the company will earn ($0.95) per share for the quarter. Jefferies Financial Group also issued estimates for Inhibrx’s Q2 2023 earnings at ($0.99) EPS, Q3 2023 earnings at ($0.94) EPS and Q4 2023 earnings at ($0.98) EPS.

Inhibrx (NASDAQ:INBX – Get Rating) last issued its quarterly earnings data on Monday, February 28th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.02). Inhibrx had a negative net margin of 1,130.80% and a negative return on equity of 176.32%. The firm had revenue of $2.86 million during the quarter, compared to the consensus estimate of $2.50 million.

Several other analysts have also recently commented on INBX. JMP Securities restated a “buy” rating and issued a $40.00 target price on shares of Inhibrx in a research report on Monday, April 11th. Zacks Investment Research raised Inhibrx from a “sell” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Wednesday, May 4th. Finally, Sumitomo Mitsui Financial Group assumed coverage on shares of Inhibrx in a research note on Wednesday, March 16th. They set an “outperform” rating and a $40.00 price objective on the stock.

INBX opened at $14.45 on Wednesday. The company has a current ratio of 6.20, a quick ratio of 6.20 and a debt-to-equity ratio of 1.44. The business’s 50 day moving average is $20.12 and its 200-day moving average is $29.90. The stock has a market cap of $563.93 million, a PE ratio of -6.72 and a beta of 3.06. Inhibrx has a twelve month low of $13.11 and a twelve month high of $47.90.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INBX. Swiss National Bank boosted its stake in Inhibrx by 5.6% during the 1st quarter. Swiss National Bank now owns 22,500 shares of the company’s stock valued at $501,000 after purchasing an additional 1,200 shares in the last quarter. M&T Bank Corp boosted its stake in Inhibrx by 9.1% during the first quarter. M&T Bank Corp now owns 11,743 shares of the company’s stock valued at $262,000 after buying an additional 975 shares in the last quarter. IndexIQ Advisors LLC acquired a new position in Inhibrx during the first quarter worth about $384,000. Victory Capital Management Inc. grew its holdings in Inhibrx by 20.5% during the first quarter. Victory Capital Management Inc. now owns 99,951 shares of the company’s stock worth $2,157,000 after acquiring an additional 16,998 shares during the period. Finally, Nisa Investment Advisors LLC raised its position in Inhibrx by 1,012.0% in the first quarter. Nisa Investment Advisors LLC now owns 11,120 shares of the company’s stock worth $248,000 after acquiring an additional 10,120 shares in the last quarter. Hedge funds and other institutional investors own 59.59% of the company’s stock.

About Inhibrx (Get Rating)

Inhibrx, Inc, a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.

Featured Stories